Lirimilast
Alternative Names: BAY 198004Latest Information Update: 02 Sep 2005
At a glance
- Originator Bayer
- Class Anti-inflammatories; Antiasthmatics; Small molecules
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Chronic obstructive pulmonary disease
- Discontinued Asthma
Most Recent Events
- 02 Sep 2005 No development reported - Phase-II for Chronic obstructive pulmonary disease in Europe (PO)
- 02 Sep 2005 No development reported - Phase-II for Chronic obstructive pulmonary disease in USA (PO)
- 12 Jul 2002 A clinical study has been added to the Respiratory Tract Disorders pharmacodynamics section